Paul W Ladenson, M.D.

Headshot of Paul W Ladenson
  • John Eager Howard Professor of Endocrinology & Metabolism
  • Professor of Medicine

Languages: English, French


Endocrinology, Metabolic Disorders, Thyroid Diseases more

Research Interests

Cardiac actions of thyroid hormone; Thyroid cancer; Thyroid hormone analogs more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


Johns Hopkins Outpatient Center (now called Levi Watkins, Jr., M.D., Outpatient Center)

Appointment Phone: 410-955-9270
601 N. Caroline St.
Baltimore, MD 21287 map
Phone: 410-502-4926 | Fax: 410-367-2042


Dr. Paul Ladenson is a professor of medicine at the Johns Hopkins University School of Medicine. He is also a professor of oncology; pathology; and radiology and radiological science. His areas of clinical expertise include Thyroid diseases, Endocrine & Metabolic disorders. 

Dr. Ladenson is the John Eager Howard Professor of Endocrinology and Metabolism.

He earned his M.D. from Harvard Medical School. He completed his residency and performed a fellowship in endocrinology, diabetes and metabolism at Massachusetts General Hospital. 

Dr. Ladenson's research interests include cardiac actions of thyroid hormone, thyroid cancer and thyroid hormone analogs.

He was recognized with the Lewis E. Braverman Lectureship Award at the 82nd Annual Meeting of the American Thyroid Association (ATA) in 2012. more


  • John Eager Howard Professor of Endocrinology & Metabolism
  • Professor of Medicine
  • Professor of Oncology
  • Professor of Pathology
  • Professor of Radiology and Radiological Science

Departments / Divisions

Centers & Institutes



  • MD; Harvard Medical School (1975)


  • Medicine; Massachusetts General Hospital (1977)


  • Medicine; Massachusetts General Hospital (1978)

Board Certifications

  • American Board of Internal Medicine (Endocrinology and Metabolism) (1981)
  • American Board of Internal Medicine (Internal Medicine) (1978)

Research & Publications

Research Summary

Dr. Ladensons research relates to clinical application of novel diagnostic and prognostic markers that could improve recognition and management of thyroid cancer, and new chemotherapeutic approaches to metastatic thyroid cancer.

Selected Publications

View all on PubMed

Roopnarinesingh N, Brennan N, Khan C, Ladenson PW, Hill-Briggs F, Kalyani RR. “Barriers to optimal diabetes care in Trinidad and Tobago: a health care Professionals' perspective.” BMC Health Serv Res. 2015 Sep 19;15(1):396. doi: 10.1186/s12913-015-1066-y.

McLeod DS, Jonklaas J, Brierley JD, Ain KB, Cooper DS, Fein HG, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Xing M, Litofsky DR, Maxon HR, Sherman SI. “Reassessing the NTCTCS staging systems for differentiated thyroid cancer, including age at diagnosis.” Thyroid. 2015 Oct;25(10):1097-105. doi: 10.1089/thy.2015.0148. Epub 2015 Aug 24.

Mammen JS, McGready J, Oxman R, Chia CW, Ladenson PW, Simonsick EM. “Thyroid hormone therapy and risk of thyrotoxicosis in community-resident older adults: findings from the Baltimore longitudinal study of aging.” Thyroid. 2015 Sep;25(9):979-86. doi: 10.1089/thy.2015.0180. Epub 2015 Aug 13.

Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI. “Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012.” J Clin Endocrinol Metab. 2015 Sep;100(9):3270-9. doi: 10.1210/JC.2015-1346. Epub 2015 Jul.

McLeod DS, Cooper DS, Ladenson PW, Whiteman DC, Jordan SJ. “Race/ethnicity and the prevalence of thyrotoxicosis in young Americans.” Thyroid. 2015 Jun;25(6):621-8. doi: 10.1089/thy.2014.0504. Epub 2015 May 8.

Ladenson, P.W.; Kristensen, J.D.; Ridgway, E.C.; Olsson, A.G.; Carlsson, B.; Klein, I.; Baxter, J.D.; Angelin, B. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010 Mar 11;362(10):906-916.

Ladenson, P.W. Thyroid Hormone Analogues: Ready for Prime Time. Thyroid. 2010 Dec 27;21(2):101-102.

Jonklaas, J.; Cooper, D.S.; Ain, K.B.; Bigos, T.; Brierley, J.D.; Haugen, B.R.; Ladenson, P.W.; Magner, J.; Ross, D.S.; Skarulis, M.C.; Steward, D.L.; Maxon, H.R.; Sherman, S.I. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010 Dec;20(12):1423-1424.

Hobbs, R.F.; Wahl, R.L.; Lodge, M.A.; Javadi, M.S.; Cho, S.Y.; Chien, D.T.; Ewertz, M.E.; Esaias, C.E.; Ladenson, P.W.; Sgouros, G. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med. 2009 Nov;50(11):1844-1847.

Prideaux, A.R.; Song, H.; Hobbs, R.F.; He, B.; Frey, E.C.; Ladenson, P.W.; Wahl, R.L.; Sgouros, G. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007 Jun;48(6):1008-1016.

Diaz, L.A., Jr.; Foss, C.A.; Thornton, K.; Nimmagadda, S.; Endres, C.J.; Uzuner, O.; Seyler, T.M.; Ulrich, S.D.; Conway, J.; Bettegowda, C.; Agrawal, N.; Cheong, I.; Zhang, X.; Ladenson, P.W.; Vogelstein, B.N.; Mont, M.A.; Zhou, S.; Kinzler, K.W.; Vogelstein, B.; Pomper, M.G. Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. PLoS One. 2007;2(10):e1007.

Song, H.; He, B.; Prideaux, A.; Du, Y.; Frey, E.; Kasecamp, W.; Ladenson, P.W.; Wahl, R.L.; Sgouros, G. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006 Dec;47(12):1985-1994.

Sgouros, G.; Song, H.; Ladenson, P.W.; Wahl, R.L. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med. 2006 Dec;47(12):1977-1984.

Hu, S.; Ewertz, M.; Tufano, R.P.; Brait, M.; Carvalho, A.L.; Liu, D.; Tufaro, A.P.; Basaria, S.; Cooper, D.S.; Sidransky, D.; Ladenson, P.W.; Xing, M. Detection of serum deoxyribonucleic acid methylation markers: a novel diagnostic tool for thyroid cancer. J Clin Endocrinol Metab. 2006 Jan;91(1):98-104.

Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the Incremental Value of Recombinant TSH Stimulation before FDG PET/CT Imaging to Localize Residual Differentiated Thyroid Cancer J Clin Endocrinol Metab 2009;94:1310-1316.

Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A Comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with rhTSH compared to thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-84. 

Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos R, Sherman S, Haugen B, Corone C, Molinaro E, Elisei, Ceccarelli C, Pinchera A, Wahl R, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-32.

Xing M, Westra WH, M.D., Tufano RP, Rosenbaum E, Cohen Y, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz ME, Tufaro AP, Califano JA, Ringel MD., Zeiger MA., Sidransky D, and Ladenson PW. BRAF mutation predicts a poorer prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9.

Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. New Engl J Med 2005;352:2406-2412.

Xing M, Tufano RP, Tufaro AP, Basaria S, Byrne PJ, Wang J, Sidransky D, Ladenson PW. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab. 2004;89:2867-72.

Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Samuels M, Graham K, Braverman LE, Skarulis M, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-3885.

Ladenson PW, Braverman LE, Mazzaferri EL, Robbins J, Cooper DS, Garber JS, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Levis S, Hay ID, McEllin K, Moscicki R, Weintraub BD. Comparison of recombinant human thyrotropin administration to thyroid hormone withdrawal for radioactive iodine scanning in patients with thyroid carcinoma. New Engl J Med 1997;337:888-96.

Activities & Honors


  • Lewis E. Braverman Lectureship Award, American Thyroid Association, 2012

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Is this you? Edit Profile
back to top button